Pulmonx Corporation (LUNG)
Pulmonx Corporation (LUNG) Now Trades Above Golden Cross: Time to Buy?
After reaching an important support level, Pulmonx Corporation (LUNG) could be a good stock pick from a technical perspective. LUNG recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Pulmonx Rebuilds Sales Force, Targets Growth and AeriSeal Launch Next Year
Pulmonx NASDAQ: LUNG is rebuilding its sales organization, targeting a return to growth and preparing for potential commercialization of its AeriSeal therapy outside the United States in the second half of next year, President and CEO Glen French said during a Canaccord fireside chat.
What Makes Pulmonx Corporation (LUNG) a Strong Momentum Stock: Buy Now?
Does Pulmonx Corporation (LUNG) have what it takes to be a top stock pick for momentum investors? Let's find out.
Pulmonx (LUNG) Upgraded to Buy: What Does It Mean for the Stock?
Pulmonx (LUNG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Pulmonx Q2 Earnings Call Highlights
Pulmonx NASDAQ: LUNG reported second-quarter revenue of $22.8 million and reiterated its full-year 2026 revenue outlook, while executives highlighted progress in rebuilding the U.S. sales organization, reducing operating expenses and preparing to resume shipments to China.
Pulmonx Corporation (LUNG) Reports Q2 Loss, Beats Revenue Estimates
Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.38 per share a year ago.
Pulmonx Corporation (LUNG) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Pulmonx Corporation (LUNG) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Pulmonx Corporation (LUNG) Q1 2026 Earnings Call Transcript
Pulmonx Corporation (LUNG) Q1 2026 Earnings Call Transcript
Pulmonx Corporation (LUNG) Reports Q1 Loss, Tops Revenue Estimates
Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.33 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.36 per share a year ago.
Pulmonx Corporation (NASDAQ:LUNG) Given Average Rating of “Hold” by Brokerages
Pulmonx Corporation (NASDAQ: LUNG - Get Free Report) has received an average recommendation of "Hold" from the eight research firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company. The average
Pulmonx Corporation (LUNG) Reports Q4 Loss, Tops Revenue Estimates
Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $0.33 per share a year ago.
Pulmonx Corporation (LUNG) Q4 2025 Earnings Call Transcript
Pulmonx Corporation (LUNG) Q4 2025 Earnings Call Transcript
